Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $1.98 million. The enterprise value is -$2.81 million.
Important Dates
The last earnings date was Friday, September 12, 2025, before market open.
| Earnings Date | Sep 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 838,787 shares outstanding. The number of shares has increased by 736.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 838,787 |
| Shares Change (YoY) | +736.36% |
| Shares Change (QoQ) | +281.40% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 3.05% |
| Float | 831,814 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.10 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.63 |
| Quick Ratio | 3.63 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.82 |
Financial Efficiency
Return on equity (ROE) is -61.77% and return on invested capital (ROIC) is -53.41%.
| Return on Equity (ROE) | -61.77% |
| Return on Assets (ROA) | -39.04% |
| Return on Invested Capital (ROIC) | -53.41% |
| Return on Capital Employed (ROCE) | -72.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$656,254 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -397,315 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.56% in the last 52 weeks. The beta is 0.96, so BDRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -94.56% |
| 50-Day Moving Average | 4.70 |
| 200-Day Moving Average | 8.55 |
| Relative Strength Index (RSI) | 39.70 |
| Average Volume (20 Days) | 2,135,676 |
Short Selling Information
| Short Interest | 494,378 |
| Short Previous Month | 124,098 |
| Short % of Shares Out | 58.94% |
| Short % of Float | 59.43% |
| Short Ratio (days to cover) | 0.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | -6.73M |
| Operating Income | -12.32M |
| Pretax Income | -8.93M |
| Net Income | -8.53M |
| EBITDA | -12.16M |
| EBIT | -12.32M |
| Earnings Per Share (EPS) | -$53.50 |
Full Income StatementBalance Sheet
The company has $5.53 million in cash and $686,395 in debt, with a net cash position of $4.84 million or $5.77 per share.
| Cash & Cash Equivalents | 5.53M |
| Total Debt | 686,395 |
| Net Cash | 4.84M |
| Net Cash Per Share | $5.77 |
| Equity (Book Value) | 15.67M |
| Book Value Per Share | 25.29 |
| Working Capital | 8.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.74 million and capital expenditures -$15,071, giving a free cash flow of -$14.49 million.
| Operating Cash Flow | -14.74M |
| Capital Expenditures | -15,071 |
| Free Cash Flow | -14.49M |
| FCF Per Share | -$17.28 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
